日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

A 12-Week Prospective, Double-Blind, Multicenter, Randomized Study Comparing 100 Units of Abobotulinum Toxin Type A (Dysport(®)) and 33.33 Units of Neubotulinum Toxin Type A (Neuronox(®)) for the Treatment of Hemifacial Spasm

一项为期 12 周的前瞻性、双盲、多中心、随机研究,比较 100 单位 A 型肉毒杆菌毒素(Dysport®)和 33.33 单位 A 型肉毒杆菌毒素(Neuronox®)治疗面肌痉挛的疗效。

Kongsaengdao, Subsai; Arayawichanont, Arkhom; Samintharapanya, Kanoksri; Rojanapitayakorn, Pichai; Maneeton, Benchalak; Maneeton, Narong

Melatonin Receptor Agonists for the Prevention of Delirium: An Updated Systematic Review and Meta-Analysis of Randomized Controlled Trials

褪黑素受体激动剂预防谵妄:随机对照试验的最新系统评价和荟萃分析

Maneeton, Benchalak; Kongsaengdao, Subsai; Maneeton, Narong; Likhitsathian, Surinporn; Woottiluk, Pakapan; Kawilapat, Suttipong; Srisurapanont, Manit

Low-Dose Neubotulinum Toxin A versus Low-Dose Abobotulinum Toxin A Injection for the Treatment of Cervical Dystonia: A Multicenter, 48-Week, Prospective, Double-Blinded, Randomized Crossover Design Study

低剂量A型肉毒杆菌毒素注射与低剂量A型肉毒杆菌毒素注射治疗颈肌张力障碍的疗效比较:一项多中心、48周、前瞻性、双盲、随机交叉设计研究

Kongsaengdao, Subsai; Arayawithchanont, Arkhom; Samintharapanya, Kanoksri; Rojanapitayakorn, Pichai; Maneeton, Benchalak; Maneeton, Narong

Long-term quality of life in cervical dystonia after treatment with abobotulinum toxin A: a 2-year prospective study

使用A型肉毒杆菌毒素治疗颈肌张力障碍后,患者的长期生活质量:一项为期2年的前瞻性研究

Kongsaengdao, Subsai; Maneeton, Narong; Maneeton, Benchalak

Quality of life in cervical dystonia after treatment with botulinum toxin A: a 24-week prospective study

肉毒杆菌毒素A治疗后颈肌张力障碍患者的生活质量:一项为期24周的前瞻性研究

Kongsaengdao, Subsai; Maneeton, Benchalak; Maneeton, Narong